| Product Code: ETC12629550 | Publication Date: Apr 2025 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
In 2024, Ireland continued to receive large molecules drug substance imports from top countries including the USA, UK, Germany, Metropolitan France, and Serbia. Despite a high concentration level indicated by the Herfindahl-Hirschman Index (HHI), the compound annual growth rate (CAGR) from 2020 to 2024 experienced a decrease of -4.18%. Furthermore, the growth rate from 2023 to 2024 plummeted by -30.16%, reflecting a challenging year for the import market of large molecules drug substances in Ireland.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ireland Large Molecules Drug Substance CDMO Market Overview |
3.1 Ireland Country Macro Economic Indicators |
3.2 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Ireland Large Molecules Drug Substance CDMO Market - Industry Life Cycle |
3.4 Ireland Large Molecules Drug Substance CDMO Market - Porter's Five Forces |
3.5 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Service Type, 2021 & 2031F |
3.6 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Molecule Type, 2021 & 2031F |
3.7 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Stage, 2021 & 2031F |
3.8 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.9 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Ireland Large Molecules Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for large molecule drug development and manufacturing services |
4.2.2 Growing trend towards outsourcing drug substance manufacturing to Contract Development and Manufacturing Organizations (CDMOs) |
4.2.3 Technological advancements in biologics and biosimilars production |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements and quality standards for large molecule drug manufacturing |
4.3.2 High initial investment costs for setting up and maintaining large molecule drug manufacturing facilities |
5 Ireland Large Molecules Drug Substance CDMO Market Trends |
6 Ireland Large Molecules Drug Substance CDMO Market, By Types |
6.1 Ireland Large Molecules Drug Substance CDMO Market, By Service Type |
6.1.1 Overview and Analysis |
6.1.2 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Service Type, 2021 - 2031F |
6.1.3 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021 - 2031F |
6.1.4 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Manufacturing, 2021 - 2031F |
6.1.5 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Analytical Services, 2021 - 2031F |
6.1.6 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Regulatory Support, 2021 - 2031F |
6.1.7 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Packaging, 2021 - 2031F |
6.2 Ireland Large Molecules Drug Substance CDMO Market, By Molecule Type |
6.2.1 Overview and Analysis |
6.2.2 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Monoclonal Antibodies, 2021 - 2031F |
6.2.3 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Recombinant Proteins, 2021 - 2031F |
6.2.4 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Peptides, 2021 - 2031F |
6.2.5 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Nucleic Acids, 2021 - 2031F |
6.2.6 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Viral Vectors, 2021 - 2031F |
6.3 Ireland Large Molecules Drug Substance CDMO Market, By Stage |
6.3.1 Overview and Analysis |
6.3.2 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Preclinical, 2021 - 2031F |
6.3.3 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021 - 2031F |
6.3.4 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021 - 2031F |
6.3.5 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Late-Stage, 2021 - 2031F |
6.3.6 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Early-Stage, 2021 - 2031F |
6.4 Ireland Large Molecules Drug Substance CDMO Market, By Application |
6.4.1 Overview and Analysis |
6.4.2 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Oncology, 2021 - 2031F |
6.4.3 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Immunology, 2021 - 2031F |
6.4.4 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Neurology, 2021 - 2031F |
6.4.5 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Rare Diseases, 2021 - 2031F |
6.4.6 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Infectious Diseases, 2021 - 2031F |
6.5 Ireland Large Molecules Drug Substance CDMO Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Pharmaceutical Companies, 2021 - 2031F |
6.5.3 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Biopharmaceutical Companies, 2021 - 2031F |
6.5.4 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Research Institutes, 2021 - 2031F |
6.5.5 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By CROs, 2021 - 2031F |
6.5.6 Ireland Large Molecules Drug Substance CDMO Market Revenues & Volume, By CMOs, 2021 - 2031F |
7 Ireland Large Molecules Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Ireland Large Molecules Drug Substance CDMO Market Export to Major Countries |
7.2 Ireland Large Molecules Drug Substance CDMO Market Imports from Major Countries |
8 Ireland Large Molecules Drug Substance CDMO Market Key Performance Indicators |
8.1 Percentage of revenue generated from large molecule drug substance manufacturing services |
8.2 Number of new partnerships or collaborations with pharmaceutical companies for large molecule drug development |
8.3 Rate of adoption of new technologies in large molecule drug manufacturing processes |
8.4 Number of regulatory approvals obtained for large molecule drug manufacturing facilities |
8.5 Percentage of customer satisfaction ratings for large molecule drug substance CDMO services |
9 Ireland Large Molecules Drug Substance CDMO Market - Opportunity Assessment |
9.1 Ireland Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Service Type, 2021 & 2031F |
9.2 Ireland Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Molecule Type, 2021 & 2031F |
9.3 Ireland Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Stage, 2021 & 2031F |
9.4 Ireland Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Application, 2021 & 2031F |
9.5 Ireland Large Molecules Drug Substance CDMO Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Ireland Large Molecules Drug Substance CDMO Market - Competitive Landscape |
10.1 Ireland Large Molecules Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 Ireland Large Molecules Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here